Amgen Inc. (AMGN)

NMS – Real vaqt narxi. Valyuta: USD

358.33

+5.51 (1.56%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

357.67

-0.66 (-0.18%)

Bozordan keyin: Jun 26, 2026, 7:57 PM EDT

15.06.2026

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation.

13.06.2026

Drugmakers race to find a place in the next wave of obesity drugs

Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.

11.06.2026

Amgen taps research firm to reassess Tavneos data

Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it seeks to prove its benefits following the U.S. health regulator's ‌proposal to withdraw it from the market.

11.06.2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

10.06.2026

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.

10.06.2026

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

10.06.2026

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Videolar

14.01.2026

Neutral

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

14.01.2026

Positive

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

13.11.2025

Positive

Trade Tracker: Bill Baruch buys more Amgen

Press-relizlar

15.06.2026

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

07.06.2026

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.

27.05.2026

Ember LifeSciences announces new strategic investments boosting Series A to $27M

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN ) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.

19.05.2026

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020.

Amgen Inc. (AMGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amgen Inc. (AMGN)

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Drugmakers race to find a place in the next wave of obesity drugs

Amgen taps research firm to reassess Tavneos data

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Videolar

Press-relizlar

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Ember LifeSciences announces new strategic investments boosting Series A to $27M

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Drugmakers race to find a place in the next wave of obesity drugs

Amgen taps research firm to reassess Tavneos data

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Videolar

Press-relizlar

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Ember LifeSciences announces new strategic investments boosting Series A to $27M

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Search stocks

Amgen Inc. (AMGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Amgen Inc. (AMGN)

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Drugmakers race to find a place in the next wave of obesity drugs

Amgen taps research firm to reassess Tavneos data

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Videolar

Press-relizlar

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Ember LifeSciences announces new strategic investments boosting Series A to $27M

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

Drugmakers race to find a place in the next wave of obesity drugs

Amgen taps research firm to reassess Tavneos data

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?

Videolar

Press-relizlar

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Ember LifeSciences announces new strategic investments boosting Series A to $27M

AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH